Breast Cancer Imaging Global Analysis and Market Forecasts. GDME0166MAR / Published May 2013

Size: px
Start display at page:

Download "Breast Cancer Imaging Global Analysis and Market Forecasts. GDME0166MAR / Published May 2013"

Transcription

1 Breast Cancer Imaging Global Analysis and Market Forecasts GDME0166MAR / Published May 2013

2 Executive Summary Breast Cancer Imaging: Key Metrics in 10 Major Device Markets 2011 Market Sales US $601m 5EU $192m APAC $142m Brazil $42m Total $972m Key Features of the Report Number of imaging techniques covered 17 Number of marketed products analyzed 51 Competitors profiled 17 Key Events ( ) Results of the Oslo Breast Cancer Screening Trial Results of the TOMMY trial GE Healthcare acquires U-Systems Food and Drug Administration (FDA) approval of GE Healthcare and Siemens Healthcare tomosynthesis systems Philips acquires Sectra Hologic acquires Beijing Healthcome Technology Results from J-START trial 2018 Market Sales US Level of Impact $1,110 m 5EU $241m APAC $231m Brazil $71m Total Source: GlobalData, EU = France, Germany, Italy, Spain, and UK; APAC = Asia-Pacific: for the purposes of this report, Japan, China, and India $1,654m GlobalData calculated the global breast cancer imaging market to be worth $972m in 2011 and estimates that it will be worth $1.7 billion in 2018, increasing at a Compound Annual Growth Rate (CAGR) of 8% during this time period. The key drivers for the global breast cancer imaging market are: Increase in the incidence of breast cancer Increased awareness of the benefits of screening Increased breast cancer incidence due to an aging population FDA reclassification of mammography equipment New technologies to drive growth in the market An increase in the age range for screening in the UK Rapid adoption of digital mammography units worldwide The key barriers for the global breast cancer imaging market are: A shortage of dedicated breast radiologists High capital Investment for full-field digital mammography (FFDM) and tomosynthesis in the face of reduced hospital budgets The trend towards buying refurbished equipment Reimbursement issues Page 2 GDME0166MAR / Published MAY 2013

3 Executive Summary Significant Unmet Needs and Challenges for the Global Breast Cancer Imaging Market Even though the global breast cancer imaging market is a mature one, it has significant needs that still have not been met. Some of these include exposure to ionizing radiation during mammographic examinations, patient discomfort due to compression of the breasts, unreliable mammograms in breasts that have been operated on and breasts with implants, a high number of false-positives and false-negatives, loss of mammography sensitivity in dense breasts, and limited training provided to technicians by equipment manufacturers. A few of these unmet needs are being addressed to a certain extent by using modalities such as ultrasound imaging and magnetic resonance imaging (MRI) in conjunction with mammography. However, there is a still a lot of room for improvement within the market, and new technologies currently in development that overcome these drawbacks show promise for the future. Future Landscape The global breast cancer imaging market is primarily driven by the increasing incidence of breast cancer and the aging population. It is also fueled by the need to overcome the drawbacks posed by mammography, which is the most widely used technique for breast cancer detection and diagnosis. GlobalData anticipates that new technologies, such as tomosynthesis, will drive the future growth of this market. Tomosynthesis is predicted to be the new gold standard in the near future due to its promising increase in cancer detection and reduction of false-positives, which are key concerns with mammography. While most experts will argue that tomosynthesis has a higher radiation dose exposure when compared with mammography, GlobalData expects that two-dimensional (2D) synthetic mammograms will provide a means of reducing the radiation dose when tomosynthesis is employed on its own. Since the US is the biggest contributor in the global breast cancer imaging market, a dip in revenues for new installations of mammography equipment was observed after 2009, when the US market started to show signs of saturation for digital mammography. The US market was estimated to contribute about 61% of the global breast cancer imaging market revenues in 2011, which dropped to 55.8% of the total revenue in However, GlobalData estimates that due to the positive reception of tomosynthesis by the radiology community, the global breast cancer imaging market is expected to emerge from its slow growth phase and gain momentum to reach $1.7 billion by 2018, of which the US will have a 67% share. Meanwhile, the European Union (EU) member states are expected to show modest growth during the forecast period, owing to a minor increase in the number of new FFDM and tomosynthesis systems. Brazil and the Asia-Pacific (APAC) regions (Japan, China, and India) will continue to grow, since digital mammography has yet to be widely adopted in these regions and the breast cancer incidence is rising steadily. Page 3 GDME0166MAR / Published MAY 2013

4 Executive Summary On the technology front, GlobalData expects a drastic decline in the worldwide use of film-screen mammography (FSM), and estimates that this segment of the breast cancer imaging market will generate zero revenues in the developed nations after FFDM 2Donly systems are expected to show a decline in the US in the near future and a modest increase in the 5EU, while the number of new installations will continue to increase in the APAC regions and Brazil. New tomosynthesis installations are expected to increase four fold by 2016 in the US and will double in the EU states, while a modest uptake is projected in the APAC regions and Brazil. What do Physicians Think? Radiologists feel that mammography is not an ideal tool for breast screening and there are significant unmet needs. Mammography is a useful tool, but it s a bad technique. Key Opinion Leader, January 2013 The biggest challenge [is] to have patient comfort [during] mammography, that s number one, I think Key Opinion Leader, January 2013 Radiologists feel strongly that tomosynthesis is very promising and will most likely replace digital mammography, the current paradigm. Mammography is a useful tool, but it s a bad technique. Key Opinion Leader, January 2013 I think there is space for everything...but the word is digital, the word is 3D.[The] breast is a 3D organ. Why should we look at [it] in 2D images? If it s [tomosynthesis] going to find more cancers and fewer recalls, then it should be a win-win. Key Opinion Leader, December 2012 I ll tell you today that I am 95% sure that tomosynthesis is mammography s future and conventional mammography is gone. Key Opinion Leader, January 2013 If I have to put money in something, I will put it in tomosynthesis and MRI [in the] short term [and in the] long term, maybe.. molecular imaging techniques. Key Opinion Leader, January 2013 Radiologists feel that the impact of tomosynthesis compared with digital mammography is much greater in comparison to the change from analog to digital mammography. The change from analog to digital mammography [in the US], went so fast, so quickly. amazing, now almost 90% [adoption]...if you look at the FDA site 90% [adoption], I mean it is incredible. So, what my way of thought is, I say, look if from analog to digital, it was not such a big deal, by that I mean it was the same technology, only digital The difference was not so big [so only small improvement], like it is from mammography to tomosynthesis. You are talking about [image] slices; you are talking about 3D [imaging] [so large improvement].i think, the gain between digital [2D FFDM] and tomo[synthesis] is much, much, much higher than it was from analog to digital. Key Opinion Leader, January 2013 Key Opinion Leader, January 2013 Page 4 GDME0166MAR / Published MAY 2013

5 Executive Summary Radiologists feel that there is not enough commitment from the manufacturers towards technician training. A banker can buy a machine much faster than anyone out there, right? But I mean the banker cannot get a good image. Key Opinion Leader, January 2013 Training is needed because if the technician has not given good positioning, whatever good factors may be there, good equipment may be there, you won t be able to see things. Key Opinion Leader, December 2012 Radiologists feel that in the future, they foresee more emphasis being placed on lowering radiation dose. [On future market trends] there is going to be more emphasis on low [radiation] dose, understanding breast density, and being efficient doing more with less. Key Opinion Leader, December 2012 If there is a good product which does good imaging and it has low [radiation] dose and it s reliable, then it may be of value. Key Opinion Leader, December 2012 Page 5 GDME0166MAR / Published MAY 2013

6 1 Table of Contents 1 Table of Contents List of Tables List of Figures Introduction Catalyst Disease Overview Anatomy & Physiology of the Breast Pathophysiology of Breast Cancer Detection of Breast Cancer Types of Breast Cancer Clinical Presentation Clinical Outcomes Assessment Procedure Screening Guidelines Epidemiology of Breast Cancer Economic Impact of Breast Cancer Imaging Imaging Techniques Mammography Overview Types of Mammography Non-Mammographic Techniques Breast Ultrasound Imaging Breast Magnetic Resonance Imaging Comparison of Mammography, Ultrasound, and MRI Alternative Breast Imaging Techniques Nuclear Imaging Techniques Computed Tomography...53 Page 6 GDME0166MAR / Published MAY 2013

7 4.4.3 Optical Breast Imaging Electric Impedance-Based Techniques Thermography Elastography Ductogram Competitive Assessment Overview Film Screen Mammography Performa (GE Healthcare) Alpha RT/Alpha ST (GE Healthcare) MAMMOMAT 1000 (Siemens Healthcare) MAMMOMAT 3000 Nova (Siemens Healthcare) M-IV/M-IV Platinum (Hologic) MammoDiagnost (Philips Healthcare) Planmed Nuance Classic (Planmed) Planmed Sophie Classic (Planmed) Analog Giotto Image (Internazionale Medico Scientifica) HAWK-2M (Hologic) MGU-1000A (Toshiba Medical Systems) CR Mammography Fuji Computed Radiography Mammography Suite (FCRMS) (Fujifilm Medical Systems) KODAK DirectView (Carestream Health) Xpress CR System (Konica Minolta) REGIUS PureView (Konica Minolta) Agfa CR Mammography Systems (DX-M, CR 30-Xm, and CR 85-X) (Agfa Healthcare) Full-Field Digital Mammography Selenia Dimensions (Hologic)...88 Page 7 GDME0166MAR / Published MAY 2013

8 5.4.2 Selenia (Hologic) Selenia S (Hologic) Selenia Performance (Hologic) Senographe DS (GE Healthcare) Senographe Essential (GE Healthcare) Senographe Care (GE Healthcare) SenoBright CESM (GE Healthcare) MAMMOMAT Inspiration (Siemens Healthcare) Aspire HD (US)/Amulet (Outside the US) (Fujifilm) MammoDiagnost DR (Philips Healthcare) MicroDose (Philips Healthcare) Giotto Image 3D/3DL (Internazionale Medico Scientifica) Planmed Nuance/Nuance Excel (Planmed) Fairy DR (Allengers Medical Systems) Serenity D Mammography Selenia Dimensions 3D System (Hologic) True 3D Breast Tomosynthesis (Siemens Healthcare) Giotto Tomo (Internazionale Medico Scientifica) FUJIFILM 3Dimensional Mammography (Fujifilm) Breast Ultrasound Imaging somo.v Automated Breast Ultrasound (ABUS) (GE Healthcare) SonoCine AWBUS (SonoCine) ACUSON S2000 ABVS (Siemens Healthcare) Terason t3200 Ultrasound System Breast Series (Terason Ultrasound) Breast MRI Aurora 1.5T Dedicated Breast MRI System (Aurora Imaging Technology) Other Breast Imaging Techniques Page 8 GDME0166MAR / Published MAY 2013

9 5.8.1 PEM Flex Solo II (Naviscan) Computerized Tomography Laser Mammography (CTLM) Model 1020 (Imaging Diagnostic Systems) Dilon 6800/Dilon 6800 Acella (Dilon Diagnostics) LumaGEM (Gamma Medica) Discovery NM 750b (GE Healthcare) Unmet Needs Lower Radiation Dose Increase Patient Comfort Reduce False-Positives and False-Negatives Loss of Sensitivity of Mammography in Dense Breasts Unreliable Mammograms in Surgically-Operated Breasts and Breasts with Implants Commitment to Training Pipeline Products Breast Cancer Imaging Pipeline Products Overview GE Breast Tomosynthesis (GE Healthcare) Overview SWOT Analysis MAMMOMAT Inspiration PRIME Edition Overview SWOT Analysis MicroDose SI Overview SWOT Analysis Selenia Dimensions 2D Contrast-Enhanced Digital Mammography (CEDM) Overview SWOT Analysis SenoCase Overview Page 9 GDME0166MAR / Published MAY 2013

10 7.6.2 SWOT Analysis Electrical Mammogram Overview SWOT Analysis Industry Overview Purchasing Cycle Product Life Cycle Cost Effectiveness in Screening Settings Cost-Effectiveness in Diagnostic Settings Market Access Purchasing Decisions Regulatory Process Quality Assurance US EU Brazil Japan China and India Adoption of New Technologies Influence of Clinical Trials Results Reimbursement Economic Resources Low Breast Cancer Incidence and Absence of a National Screening Program Competitive Advantage Current Reimbursement Trends US Europe France Page 10 GDME0166MAR / Published MAY 2013

11 8.5.4 Germany Italy Spain UK TJapan Brazil TChina TIndia Trends in Detector Technology for Digital Mammography Evolving Scatter-Removal Mechanisms Overdiagnosis Malpractice Litigations Mergers and Acquisitions/Key Partnerships GE Healthcare Acquires U-Systems Koninklijke Philips Electronics Acquires MicroDose Mammography from Sectra Hologic Acquires Beijing Healthcome Technology Hologic Acquires Sentinelle Medica Koninklijke Philips Electronics Acquires Shanghai Apex Electronics Technology Fujifilm Medical Systems acquired FUJIFILM-RU Other Key Events Current and Future Players Overview Trends in Corporate Strategy Company Profiles GE Healthcare Hologic Siemens Koninklijke Philips Electronics Page 11 GDME0166MAR / Published MAY 2013

12 9.3.5 Fujifilm Medical Systems Internazionale Medico Scientifica (IMS) Planmed Konica Minolta Medical Imaging Agfa Healthcare Carestream Health SonoCine Aurora Imaging Technology Imaging Diagnostic Systems Naviscan Dilon Diagnostics Gamma Medica Allengers Medical Systems Market Drivers & Opportunities Market Drivers Increase in the Incidence of Breast Cancer Increased Awareness of the Benefits of Screening Increased Breast Cancer Incidence Due to an Aging Population FDA Reclassification of Mammography Equipment New Technologies to Drive Market Growth Changes in Age Inclusion Criteria in Breast Cancer Screening Programs Adoption of Digital Mammography Units Worldwide Opportunities Emerging Economies Promise Future Growth Invest in Emerging Technologies Product Improvement Market Barriers Shortage of Dedicated Mammography Professionals Page 12 GDME0166MAR / Published MAY 2013

13 Reduced Hospital Budgets Refurbished Equipment Sales Reimbursement Substitutes Country Outlooks & Forecasts Major Markets Overview United States United States Market Analysis France France Market Analysis Germany Germany Market Analysis Italy Italy Market Analysis Spain Spain Market Analysis United Kingdom United Kingdom Market Analysis Japan Japan Market Analysis Brazil Brazil Market Analysis China China Market Analysis India India Market Analysis Appendix Bibliography Page 13 GDME0166MAR / Published MAY 2013

14 12.2 Abbreviations Report Methodology Overview Coverage Secondary Research Forecast Methodology Physicians and Specialists Included in this Study Primary Research Physician Survey About the Authors Analysts Global Head of Healthcare Definitions About MediPoint About GlobalData Contact Us Disclaimer Page 14 GDME0166MAR / Published MAY 2013

15 1.1 List of Tables Table 1: Breast Cancer Types, Including Diagnostic Procedures...29 Table 2: ACR Breast Imaging Reporting and Database System (BI-RADS)...31 Table 3: Selected Breast Cancer Incidence Rates, Table 4: Comparison of Mammography, Ultrasound, and MRI for Breast Imaging...50 Table 5: Performa Product Profile...58 Table 6: Performa SWOT Analysis...59 Table 7: Alpha RT/Alpha ST Product Profile...61 Table 8: Alpha RT/Alpha ST SWOT Analysis...62 Table 9: MAMMOMAT 1000 Product Profile...63 Table 10: MAMMOMAT 1000 SWOT Analysis...64 Table 11: MAMMOMAT 3000 Nova Product Profile...66 Table 12: MAMMOMAT 3000 Nova SWOT Analysis...66 Table 13: M-IV/M-IV Platinum Product Profile...68 Table 14: M-IV/M-IV Platinum SWOT Analysis...68 Table 15: MammoDiagnost Product Profile...70 Table 16: MammoDiagnost SWOT Analysis...70 Table 17: Planmed Nuance Classic Product Profile...72 Table 18: Planmed Nuance Classic SWOT Analysis...72 Table 19: Planmed Sophie Classic Product Profile...73 Table 20: Planmed Sophie Classic SWOT Analysis...74 Table 21: Analog Giotto Image Product Profile...75 Table 22: Analog Giotto Image SWOT Analysis...75 Table 23: HAWK-2M Product Profile...77 Table 24: HAWK-2M SWOT Analysis...77 Table 25: MGU-1000A Product Profile...78 Table 26: MGU-1000A SWOT Analysis...79 Table 27: Fuji Computed Radiography Mammography Suite (FCRMS) Product Profile...81 Page 15 GDME0166MAR / Published MAY 2013

16 Table 28: Fuji Computed Radiography Mammography Suite (FCRMS) SWOT Analysis...81 Table 29: KODAK DirectView CR System Product Profile...82 Table 30: KODAK DirectView CR System SWOT Analysis...83 Table 31: Xpress CR System Product Profile...84 Table 32: Xpress CR System SWOT Analysis...84 Table 33: REGIUS PureView Product Profile...85 Table 34: REGIUS PureView SWOT Analysis...86 Table 35: Agfa CR Mammography Systems (DX-M, CR 30-Xm, and CR 85-X) Product Profile...87 Table 36: Agfa CR Mammography Systems (DX-M, CR 30-Xm, and CR 85-X) SWOT Analysis...87 Table 37: FFDM SWOT Analysis...88 Table 38: Selenia Dimensions Product Profile...89 Table 39: Selenia Dimensions SWOT Analysis...90 Table 40: Selenia Product Profile...92 Table 41: Selenia SWOT Analysis...92 Table 42: Selenia S Product Profile...93 Table 43: Selenia S SWOT Analysis...94 Table 44: Selenia Performance Product Profile...95 Table 45: Selenia Performance SWOT Analysis...95 Table 46: Senographe DS Product Profile...96 Table 47: Senographe DS SWOT Analysis...97 Table 48: Senographe Essential/Senographe Essential E Product Profile...98 Table 49: Senographe Essential SWOT Analysis...99 Table 50: Senographe Care Product Profile Table 51: Senographe Care SWOT Analysis Table 52: SenoBright CESM Product Profile Table 53: SenoBright CESM SWOT Analysis Table 54: MAMMOMAT Inspiration Product Profile Page 16 GDME0166MAR / Published MAY 2013

17 Table 55: MAMMOMAT Inspiration SWOT Analysis Table 56: Aspire HD/Amulet Product Profile Table 57: Aspire HD/Amulet SWOT Analysis Table 58: MammoDiagnost DR Product Profile Table 59: MammoDiagnost DR SWOT Analysis Table 60: MicroDose Product Profile Table 61: MicroDose SWOT Analysis Table 62: Giotto Image 3D/3DL Product Profile Table 63: Giotto Image 3D/3DL SWOT Analysis Table 64: Planmed Nuance/Nuance Excel Product Profile Table 65: Planmed Nuance/Nuance Excel SWOT Analysis Table 66: Fairy DR Product Profile Table 67: Fairy DR SWOT Analysis Table 68: Serenity Product Profile Table 69: Serenity SWOT Analysis Table 70: Selenia Dimensions 3D System Product Profile Table 71: Selenia Dimensions SWOT Analysis Table 72: True 3D Breast Tomosynthesis Product Profile Table 73: True 3D Breast Tomosynthesis SWOT Analysis Table 74: Giotto Tomo Product Profile Table 75: Giotto Tomo SWOT Analysis Table 76: FUJIFILM 3Dimensional Mammography Product Profile Table 77: FUJIFILM 3Dimensional Mammography SWOT Analysis Table 78: somo.v ABUS Product Profile Table 79: somo.v ABUS SWOT Analysis Table 80: SonoCine AWBUS Product Profile Table 81: SonoCine AWBUS SWOT Analysis Table 82: ACUSON S2000 ABVS Product Profile Page 17 GDME0166MAR / Published MAY 2013

18 Table 83: Acuson S2000 ABVS SWOT Analysis Table 84: Terason t3200 Ultrasound System Breast Series Product Profile Table 85: Terason t3200 Ultrasound System Breast Series SWOT Analysis Table 86: Aurora 1.5T Dedicated Breast MRI System Product Profile Table 87: Aurora 1.5T Dedicated Breast SWOT Analysis Table 88: PEM Flex Solo II Product Profile Table 89: PEM Flex Solo II SWOT Analysis Table 90: Computerized Tomography Laser Mammography (CTLM) Model 1020 Product Profile Table 91: Computerized Tomography Laser Mammography (CTLM) Model 1020 SWOT Analysis Table 92: Dilon 6800/Dilon 6800 Acella Product Profile Table 93: Dilon 6800/Dilon 6800 Acella SWOT Analysis Table 94: LumaGEM Product Profile Table 95: LumaGEM SWOT Analysis Table 96: Discovery NM 750b Product Profile Table 97: Discovery NM 750b SWOT Analysis Table 98: Breast Cancer Imaging Pipeline Products Table 99: GE Breast Tomosynthesis SWOT Analysis Table 100: MAMMOMAT Inspiration PRIME Edition SWOT Analysis Table 101: Philips MicroDose SI SWOT Analysis Table 102: Selenia Dimensions 2D Contrast Imaging SWOT Analysis Table 103: SenoCase SWOT Analysis Table 104: Electrical Mammogram SWOT Analysis Table 105: Other Key Events in the Breast Cancer Imaging Market Table 106: GE Healthcare SWOT Analysis, Table 107: Hologic SWOT Analysis, Table 108: Siemens SWOT Analysis, Table 109: Koninklijke Philips Electronics SWOT Analysis, Page 18 GDME0166MAR / Published MAY 2013

19 Table 110: Fujifilm Medical Systems, SWOT Analysis, Table 111: Internazionale Medico Scientifica SWOT Analysis, Table 112: Planmed, SWOT Analysis, Table 113: Konica Minolta Medical Imaging, SWOT Analysis, Table 114: Agfa Healthcare, SWOT Analysis, Table 115: Carestream Health, SWOT Analysis, Table 116: SonoCine, SWOT Analysis, Table 117: Aurora Imaging Technology, SWOT Analysis, Table 118: Imaging Diagnostic Systems, SWOT Analysis, Table 119: Naviscan, SWOT Analysis, Table 120: Dilon Diagnostics, SWOT Analysis, Table 121: Gamma Medica, SWOT Analysis, Table 122: Allengers Medical Systems, SWOT Analysis, Table 123: Major Events Affecting the Global Breast Cancer Imaging Market Table 124: Sales Forecasts for Breast Cancer Imaging in the 10 Major Markets, Table 125: Global Forecast for Numbers of Breast Cancer Imaging Systems (Installed Base), Table 126: Sales Forecasts for Breast Cancer Imaging in the US, Table 127: Number of Installations of New Breast Imaging Systems in the US, 2011 and Table 128: Sales Forecasts for Breast Cancer Imaging in France, Table 129: Sales Forecasts for Breast Cancer Imaging in Germany, Table 130: Sales Forecasts for Breast Cancer Imaging in Italy, Table 131: Sales Forecasts for Breast Cancer Imaging in Spain, Table 132: Sales Forecasts for Breast Cancer Imaging in the UK, Table 133: Sales Forecasts for Breast Cancer Imaging in Japan, Table 134: Sales Forecasts for Breast Cancer Imaging in Brazil, Table 135: Sales Forecasts for Breast Cancer Imaging in China, Table 136: Sales Forecasts for Breast Cancer Imaging in India, Page 19 GDME0166MAR / Published MAY 2013

20 Table 137: Physicians Surveyed, By Country List of Figures Figure 1: Anatomy of the Breast...26 Figure 2: Breast Cancer Screening, Diagnostic Evaluation, and Follow-Up...32 Figure 3: Percentage Use of Ultrasound Imaging and MRI for Breast Cancer Screening and Follow-Up, Figure 4: Breast Cancer Risk Factors...37 Figure 5: Average Worldwide Breast Cancer Incidence, CAGR, Figure 6: Global Trends in Breast Cancer Incidence, Figure 7: Comparison Between Digital (FFDM) and Analog (FSM) Mammography...44 Figure 8: Use of Alternative Breast Imaging Modalities, Figure 9: Performa...58 Figure 10: Alpha RT...60 Figure 11: Alpha ST...61 Figure 12: MAMMOMAT Figure 13: MAMMOMAT 3000 Nova...65 Figure 14: M-IV/M-IV Platinum...67 Figure 15: MammoDiagnost...69 Figure 16: Planmed Nuance Classic...71 Figure 17: Planmed Sophie Classic...73 Figure 18: Analog Giotto Image...74 Figure 19: HAWK-2M...76 Figure 20: MGU-1000A...78 Figure 21: Aspire CRm...80 Figure 22: KODAK DirectView CR System...82 Figure 23: Xpress CR System...83 Figure 24: REGIUS PureView Type M...85 Figure 25: DX-M Digitizer...86 Page 20 GDME0166MAR / Published MAY 2013

21 Figure 26: Selenia Dimensions...89 Figure 27: Selenia...91 Figure 28: Selenia S...93 Figure 29: Selenia Performance...94 Figure 30: Senographe DS...96 Figure 31: Senographe Essential...98 Figure 32: Senographe Care Figure 33: SenoBright CESM* Figure 34: MAMMOMAT Inspiration Figure 35: Aspire HD Figure 36: MammoDiagnost DR Figure 37: MicroDose Figure 38: Giotto Image 3D/3DL Figure 39: Planmed Nuance/Nuance Excel Figure 40: Fairy DR Figure 41: Serenity Figure 42: Selenia Dimensions 2D System Figure 43: True 3D Breast Tomosynthesis* Figure 44: Giotto Tomo Figure 45: Fujifilm 3D Mammography Viewer Figure 46: somo.v ABUS Figure 47: SonoCine AWBUS Figure 48: ACUSON S2000 ABVS Figure 49: Terason t3200 Ultrasound System Breast Series Figure 50: Aurora 1.5T Dedicated Breast MRI System Figure 51: PEM Flex Solo II Figure 52: CTLM Model Figure 53: Dilon 6800 Acella Page 21 GDME0166MAR / Published MAY 2013

22 Figure 54: Dilon Figure 55: LumaGEM Figure 56: Discovery NM 750b Figure 57: Percentage of False-Positive, False-Negative and Accurate Breast Cancer Diagnoses from Figure 58: Senographe Essential Figure 59: SenoCase Figure 60: Product Life Cycle Figure 61: Breast Screening Programs in the EU Figure 62: Detector Evolution Figure 63: Comparison Between a Typical Direct Conversion Detector and a Direct Optical Switching Detector Figure 64: Photon-Counting Detector Technology Figure 65: Linear and High Transmission Cellular Grids Figure 66: Increase in FFDM Systems in the US, Figure 67: Trends in the Use of Mammographic Techniques, Figure 68: Sales Forecasts for Breast Cancer Imaging in the 10 Major Markets, Figure 69: Global Breast Cancer Imaging Market Revenue, by Region, 2011 and Figure 70: Sales Forecasts for Breast Cancer Imaging in the US, Figure 71: Total Number of Breast Imaging Facilities and Total Number of Facilities with FFDM Units in the US, Figure 72: Percentage of Installations of New Breast Imaging Systems in the US in 2011 and Figure 73: Sales Forecasts for Breast Cancer Imaging in France, Figure 74: Sales Forecasts for Breast Cancer Imaging in Germany, Figure 75: Sales Forecasts for Breast Cancer Imaging in Italy, Figure 76: Sales Forecasts for Breast Cancer Imaging in Spain, Figure 77: Sales Forecasts for Breast Cancer Imaging in the UK, Figure 78: Sales Forecasts for Breast Cancer Imaging in Japan, Page 22 GDME0166MAR / Published MAY 2013

23 Figure 79: Sales Forecasts for Breast Cancer Imaging in Brazil, Figure 80: Sales Forecasts for Breast Cancer Imaging in China, Figure 81: Sales Forecasts for Breast Cancer Imaging in India, Page 23 GDME0166MAR / Published MAY 2013

24 Introduction 2 Introduction Breast cancer is the most common form of cancer in women in both the developed and developing world, but is a rare disease in men. The global incidence of breast cancer is increasing due to an increased lifespan and increasing adoption of a westernized lifestyle, which is associated with an increased risk of the disease. Early diagnosis of breast cancer is the foundation for increasing survival rates, and diagnostic imaging is the most widely used technique to achieve early detection, making it a cornerstone of breast cancer control. Diagnostic imaging is used for the early detection of breast cancer in asymptomatic patients in population-based screening programs in most developed countries, or for opportunistic screening in developing nations. Regardless of these differences, imaging has proved to be an indispensable tool in fighting breast cancer and has been proven to reduce mortality. This report provides an analysis of the mammography market in relation to dedicated breast cancer screening and diagnosis in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the APAC regions, including Japan, China, and India, and identifies the unmet needs in the market. This report also discusses physician attitudes towards current breast cancer screening and diagnostic techniques, and the future of breast cancer imaging modalities in the face of rapid technological advancements. Page 24 GDME0166MAR / Published MAY 2013

25 Introduction 2.1 Catalyst The global breast cancer imaging market is a mature industry with complex dynamics. The dynamics of this industry vary greatly from one market to another. The main differences are due to differences in the breast cancer incidence, the presence or absence of nationwide screening programs, reimbursement issues, lifestyle factors, and differences in breast density. Therefore, it is essential to examine the market opportunities and barriers that are specific to each region. This report provides an in-depth review of the evolving technologies and the regulatory landscape in the breast cancer screening markets around the world. Another key issue is that purchasing decisions concerning breast cancer screening and diagnostic imaging equipment are complex. Firstly, breast cancer screening and diagnosis involves the challenge of making major purchasing decisions concerning new capital equipment in a technologically fast-evolving market. Secondly, diagnostic imaging modalities are often multipurpose in nature, and so equipment purchasing decisions are not solely driven by the needs of breast cancer screening and diagnosis. For example, a diagnostic mammogram is accompanied by ultrasound imaging in over 50% of cases, but the ultrasound equipment also has various other applications for imaging other parts of the human body. Since the prevalence of breast cancer is higher in women than in men, this report is restricted to the use of imaging techniques for breast cancer screening and diagnosis in women. Page 25 GDME0166MAR / Published MAY 2013

26 Appendix 12.9 About MediPoint MediPoint is the flagship product for GlobalData s Medical team. Each MediPoint report is built from the ground up by our team of healthcare analysts in the US and UK. Each report includes input from experienced physicians and leading Key Opinion Leaders (KOLs). Running throughout each report in the series, What Physicians Think quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists About GlobalData GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical R&D. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team. GlobalData has offices in New York, Boston, London, India, and Singapore. Page 283 GDME0166MAR / Published MAY 2013

27 Appendix Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the publisher, GlobalData. Page 284 GDME0166MAR / Published MAY 2013

REFERENCE CODE GDME0188M AR PUBLICATION DATE FEBRUARY 2014 BIOPSY DEVICES - GLOBAL ANALYSIS AND MARKET FORECASTS

REFERENCE CODE GDME0188M AR PUBLICATION DATE FEBRUARY 2014 BIOPSY DEVICES - GLOBAL ANALYSIS AND MARKET FORECASTS REFERENCE CODE GDME0188M AR PUBLICATION DATE FEBRUARY 2014 BIOPSY DEVICES - Executive Summary The table below provides an overview of the global biopsy devices market during the forecast period from 2013

More information

REFERENCE CODE GDME1086CFR PUBLICAT ION DATE FEBRUARY 2014 BIOPSY DEVICES APAC ANALYSIS AND MARKET FORECASTS

REFERENCE CODE GDME1086CFR PUBLICAT ION DATE FEBRUARY 2014 BIOPSY DEVICES APAC ANALYSIS AND MARKET FORECASTS REFERENCE CODE GDME1086CFR PUBLICAT ION DATE FEBRUARY 2014 BIOPSY DEVICES Executive Summary The table below provides an overview of the APAC biopsy devices market during the forecast period from 2013 2019.

More information

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India

More information

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India

More information

Brochure More information from

Brochure More information from Brochure More information from http://www.researchandmarkets.com/reports/2375238/ Breast Imaging Technologies Market (Digital Mammography,3D Breast Tomosynthesis, Breast MRI, Breast Ultrasound, Molecular

More information

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012

More information

Cyclokat (Dry Eye Syndrome)

Cyclokat (Dry Eye Syndrome) Cyclokat (Dry Eye Syndrome) Forecast and Market Analysis to 2022 GDHC191DFR / Published July 2013 Executive Summary Below table provides a summary of the key metrics for Cyclokat in the major pharmaceuticals

More information

Mammography Equipment Market to 2019

Mammography Equipment Market to 2019 Mammography Equipment Market to 2019 Growth Driven by Technical Advances in Digital Radiography that Enhance Workflow and Improve Breast Cancer Detection GBI Research Report Guidance GBI Research Report

More information

Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes

Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes EU Analysis and Market Forecasts GDME1026CFR / Published April 2013 Executive Summary Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes:

More information

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - Executive Summary Menomune: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU

More information

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m

More information

REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - Executive Summary Below table provides a summary of Belviq for obesity in the nine major pharmaceutical markets during the forecast

More information

Diquas (Dry Eye Syndrome)

Diquas (Dry Eye Syndrome) Diquas (Dry Eye Syndrome) Forecast and Market Analysis to 2022 GDHC187DFR / Published July 2013 Executive Summary Below table provides a summary of the key metrics for Diquas in the global Dry Eye Syndrome

More information

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major

More information

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets

More information

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) Executive Summary Nimenrix: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan

More information

Dry Eye Syndrome. US Drug Forecast and Market Analysis to GDHC1115CFR / Published May 2013

Dry Eye Syndrome. US Drug Forecast and Market Analysis to GDHC1115CFR / Published May 2013 Dry Eye Syndrome US Drug Forecast and Market Analysis to 2022 GDHC1115CFR / Published May 2013 Executive Summary Sales for Dry Eye Syndrome in the US The Dry Eye Syndrome (DES) market in the US will grow

More information

REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013

REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013 REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013 Executive Summary Diovan (valsartan): Key Metrics in the Seven Major Pharmaceutical Markets* 2012 Market Sales US - Diovan 5EU - Diovan Japan - Diovan

More information

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List

More information

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif

More information

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the

More information

Rituxan (Rheumatoid Arthritis)

Rituxan (Rheumatoid Arthritis) Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1008DFR / Published November 2012 Executive Summary Rituxan: Key Metrics in Rheumatoid Arthritis Markets 2012 Rituxan Sales Total 7 MM $835m

More information

Orencia (Rheumatoid Arthritis)

Orencia (Rheumatoid Arthritis) Orencia (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1006DFR / Published November 2012 Executive Summary Orencia: Key Metrics in Rheumatoid Arthritis Markets 2012 Orencia Sales Total 7 MM $831m

More information

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor

More information

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020 BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...

More information

Asia-Pacific Electrophysiology Market Outlook to 2020

Asia-Pacific Electrophysiology Market Outlook to 2020 Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...

More information

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020 Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3

More information

REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Dupilumab in the nine major pharmaceutical markets

More information

REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG Executive Summary Sales for Chronic Heart Failure in the Japan The Japan Chronic heart failure (CHF) therapeutics

More information

EU5 Bariatric Surgery Procedures Outlook to 2020

EU5 Bariatric Surgery Procedures Outlook to 2020 EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013

More information

Actemra (Rheumatoid Arthritis)

Actemra (Rheumatoid Arthritis) Actemra (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1007DFR / Published November 2012 Executive Summary Actemra: Key Metrics in Rheumatoid Arthritis Markets 2012 Actemra Sales Total 7 MM $355m

More information

LUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS) - FORECAST AND MARKET ANALYSIS TO 2022

LUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC279DFR PUBLICATION DATE OCTOBER 2013 LUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND Executive Summary Table below presents the key metrics of Lupuzor for Systemic Lupus Erythematosus (SLE)

More information

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019 Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general

More information

REFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Qutenza in the 7MM neuropathic pain markets during

More information

REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 BRODALUMAB (PSORIASIS) - Executive Summary Table below presents key metrics for brodalumab in seven of the nine major pharmaceutical markets covered

More information

REFERENCE CODE GDHC423DFR PUBLICAT ION DATE M AY 2014 ABILIFY (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC423DFR PUBLICAT ION DATE M AY 2014 ABILIFY (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC423DFR PUBLICAT ION DATE M AY 2014 ABILIFY (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Abilify in the seven major pharmaceutical markets

More information

REFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Lidoderm/Versatis in the 7MM neuropathic

More information

REFERENCE CODE GDHC013POA PUBLICAT ION DATE DECEM BER 2013

REFERENCE CODE GDHC013POA PUBLICAT ION DATE DECEM BER 2013 REFERENCE CODE GDHC013POA PUBLICAT ION DATE DECEM BER 2013 ACUTE ISCHEMIC STROKE - Executive Summary Acute Ischemic Stroke: Key Metrics in Six Major Pharmaceutical Markets 2012 Epidemiology Prevalent Cases

More information

REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Prometheus Lotronex for irritable bowel syndrome

More information

REFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - Executive Summary The Table below presents the key metrics of Ironwood/Actavis/Almirall/Astellas Linzess for

More information

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013 Kaletra (HIV) Forecast and Market Analysis to 2022 GDHC1051DFR/ Published January 2013 Executive Summary Kaletra Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US - Kaletra 5EU

More information

REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets

More information

REFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - Executive Summary The table below summarizes the key metrics for Safinamide in the 8MM Parkinson s disease (PD)

More information

REFERENCE CODE GDHC420DFR PUBLICAT ION DATE M AY 2014 FETZIMA (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC420DFR PUBLICAT ION DATE M AY 2014 FETZIMA (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC420DFR PUBLICAT ION DATE M AY 2014 FETZIMA (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Fetzima in the seven major pharmaceutical markets

More information

REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Brintellix in the seven major pharmaceutical markets

More information

Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML) Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is

More information

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013 Dry Eye Syndrome - Current and Future Players GDHC1016FPR / Published May 2013 Executive Summary Significant growth is expected in the DES market from 2012-2022. GlobalData estimates 2012 DES therapeutic

More information

Synribo (Chronic Myeloid Leukemia)

Synribo (Chronic Myeloid Leukemia) Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales

More information

REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Apokyn in the 8MM Parkinson s Disease

More information

REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS

REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - Executive Summary Human PapillomaVirus (HPV) Vaccine Sales Expected to Grow Modestly During the Forecast

More information

REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Furiex (Actavis) s eluxadoline for Irritable

More information

REFERENCE CODE GDHC401DFR PUBLICAT ION DATE M ARCH 2014 RYTARY/IPX066 (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC401DFR PUBLICAT ION DATE M ARCH 2014 RYTARY/IPX066 (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC401DFR PUBLICAT ION DATE M ARCH 2014 RYTARY/IPX066 (PARKINSON S DISEASE) - Executive Summary The table below summarizes the key metrics for Rytary/IPX066 in the 8MM Parkinson s disease

More information

REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) Executive Summary Table below provides a summary of the key metrics for Cariprazine in the seven major pharmaceutical

More information

Keppra (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1061DFR Publication Date: February 2013

Keppra (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1061DFR Publication Date: February 2013 Keppra (Epilepsy) Forecast and Market Analysis to 2022 Reference Code: GDHC1061DFR Publication Date: February 2013 Executive Summary Keppra (levetiracetam) Key Metrics in the Nine Major Pharmaceutical

More information

REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - India Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in India 2012 We estimate the 2012 PsO drug

More information

REFERENCE CODE GDHC317DFR PUBLICAT ION DATE DECEMBER 2013 LUCENTIS (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC317DFR PUBLICAT ION DATE DECEMBER 2013 LUCENTIS (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC317DFR PUBLICAT ION DATE DECEMBER 2013 LUCENTIS Executive Summary The table below presents a summary of the key metrics for Lucentis (Microvascular Complications for Diabetes) for recombinant

More information

REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of AstraZeneca/Ardelyx s tenapanor for Irritable

More information

Mexico Ostomy Drainage Bags Market Outlook to 2020

Mexico Ostomy Drainage Bags Market Outlook to 2020 Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...

More information

REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Nouriast in the 8MM Parkinson s Disease

More information

REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Stalevo/Comtan in the 8MM Parkinson

More information

REFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for cariprazine in the Major Depressive Disorder (MDD)

More information

REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 PARKINSON S DISEASE - EPIDEMIOLOGY FORECAST TO 2022

REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 PARKINSON S DISEASE - EPIDEMIOLOGY FORECAST TO 2022 REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 Executive Summary Parkinson s disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer s

More information

Lamictal (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1062DFR Publication Date: February 2013

Lamictal (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1062DFR Publication Date: February 2013 Lamictal (Epilepsy) Forecast and Market Analysis to 2022 Reference Code: GDHC1062DFR Publication Date: February 2013 Executive Summary Lamictal (lamotrigine) Key Metrics in the Nine Major Pharmaceutical

More information

REFERENCE CODE GDHC321DFR PUBLICAT ION DATE DECEMBER 2013 ATRASENTAN (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC321DFR PUBLICAT ION DATE DECEMBER 2013 ATRASENTAN (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC321DFR PUBLICAT ION DATE DECEMBER 2013 Executive Summary The table below presents a summary of the key metrics for Atrasentan (Microvascular Complications for Diabetes) in the seven

More information

REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Duodopa in the 8MM Parkinson s Disease

More information

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major

More information

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major

More information

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical

More information

REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for brexpiprazole in the Major Depressive Disorder

More information

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to GDHC1150DFR / Published May 2013

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to GDHC1150DFR / Published May 2013 Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1150DFR / Published May 2013 Executive Summary Sofosbuvir and Sofosbuvir/Ledipasvir: Key Metrics in Nine

More information

REFERENCE CODE GDHC319DFR PUBLICAT ION DATE DECEMBER 2013 EYLEA (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC319DFR PUBLICAT ION DATE DECEMBER 2013 EYLEA (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC319DFR PUBLICAT ION DATE DECEMBER 2013 EYLEA Executive Summary The table below presents a summary of the key metrics for Eylea (Microvascular Complications for Diabetes) for recombinant

More information

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report

More information

REFERENCE CODE GDHCER046 PUBLICAT ION DATE OCTOBER 2013 DIABETIC FOOT ULCERS - EPIDEMIOLOGY FORECAST TO 2022

REFERENCE CODE GDHCER046 PUBLICAT ION DATE OCTOBER 2013 DIABETIC FOOT ULCERS - EPIDEMIOLOGY FORECAST TO 2022 REFERENCE CODE GDHCER046 PUBLICAT ION DATE OCTOBER 2013 DIABETIC FOOT ULCERS - Executive Summary Diabetic foot ulcers (DFUs) are a major complication of diabetes that occurs as a result of trauma to or

More information

Volume 14 - Issue 3, Matrix

Volume 14 - Issue 3, Matrix Volume 14 - Issue 3, 2014 - Matrix Digital Breast Tomosynthesis for Screening and Diagnosis of Breast Cancer Author ECRI ECRI Institute 29 Broadwater Road Suite 104 Welwyn Garden City AL7 3BQ United Kingdom

More information

REFERENCE CODE GDME0190M AR PUBLICATION DATE JUNE 2014 SPINAL FUSION GLOBAL ANALYSIS AND MARKET FORECASTS

REFERENCE CODE GDME0190M AR PUBLICATION DATE JUNE 2014 SPINAL FUSION GLOBAL ANALYSIS AND MARKET FORECASTS REFERENCE CODE GDME0190M AR PUBLICATION DATE JUNE 2014 SPINAL FUSION Executive Summary Overview of Global Spinal Fusion Market* Procedure Volumes (in thousands) 2013 2020 Global 1,921 3,420 US 794 1,144

More information

REFERENCE CODE GDHC1042FPR PUBLICAT ION DATE DECEMBER 2014 IRRITABLE BOWEL SYNDROME CURRENT AND FUTURE PLAYERS

REFERENCE CODE GDHC1042FPR PUBLICAT ION DATE DECEMBER 2014 IRRITABLE BOWEL SYNDROME CURRENT AND FUTURE PLAYERS REFERENCE CODE GDHC1042FPR PUBLICAT ION DATE DECEMBER 2014 IRRITABLE BOWEL SYNDROME Executive Summary Sales of Irritable Bowel Syndrome Market The Irritable Bowel Syndrome (IBS) market in the 7MM (US,

More information

REFERENCE CODE GDHC482DFR PUBLICAT ION DATE OCTOBER 2014 EYLEA (MACULAR EDEMA AND MACULAR DEGENERATION) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC482DFR PUBLICAT ION DATE OCTOBER 2014 EYLEA (MACULAR EDEMA AND MACULAR DEGENERATION) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC482DFR PUBLICAT ION DATE OCTOBER 2014 EYLEA (MACULAR EDEMA AND MACULAR DEGENERATION) - Executive Summary Table below presents the key metrics of Eylea for macular edema (ME) and age-related

More information

REFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA US DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA US DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA Executive Summary Schizophrenia Sales in the US, 2012 The combined sales of medications carrying an indication in schizophrenia in

More information

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2

More information

PegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013

PegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013 PegIntron (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1143DFR / Published May 2013 Executive Summary PegIntron (peginterferon alfa-2b) Key Metrics in the Major Pharmaceutical Markets 2012

More information

REFERENCE CODE GDHC357DFR PUBLICAT ION DATE FEBRUARY 2014 CLOZARIL (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC357DFR PUBLICAT ION DATE FEBRUARY 2014 CLOZARIL (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC357DFR PUBLICAT ION DATE FEBRUARY 2014 CLOZARIL (SCHIZOPHRENIA) Executive Summary Clozaril: Key Metrics in the Seven Major Pharmaceutical Markets, 2012 2022 2012 Market Sales US 5EU

More information

REFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS US DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS US DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS Executive Summary Sales for Atopic Dermatitis 2012 in US The US Atopic dermatitis market was worth approximately $1.35 billion

More information

REFERENCE CODE GDHC361DFR PUBLICAT ION DATE FEBRUARY 2014 INVEGA (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC361DFR PUBLICAT ION DATE FEBRUARY 2014 INVEGA (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC361DFR PUBLICAT ION DATE FEBRUARY 2014 INVEGA (SCHIZOPHRENIA) Executive Summary Invega : Key Metrics in the Seven Major Pharmaceutical Markets, 2012 2022 2012 Market Sales US 5EU Japan

More information

REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Empagliflozin for Type 2 diabetes in the 10 major pharmaceutical

More information

REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - Executive Summary Botox: Key Metrics in the 7MM* for Migraine, 2012-2023 2012 Market Sales US $434.3m 5 EU $68.3m Japan Total

More information

REFERENCE CODE GDHC334DFR PUBLICAT ION DATE J ANU ARY 2014 ENGERIX-B (PROPHYLACTIC HEPATITIS B VIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC334DFR PUBLICAT ION DATE J ANU ARY 2014 ENGERIX-B (PROPHYLACTIC HEPATITIS B VIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC334DFR PUBLICAT ION DATE J ANU ARY 2014 ENGERIX-B (PROPHYLACTIC HEPATITIS B VIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary The table below provides a summary

More information

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product

More information

REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Januvia for Type 2 diabetes in the 10 major pharmaceutical markets

More information

REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 FASIGLIFAM (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 FASIGLIFAM (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 Executive Summary Fasiglifam (TAK-875): Key Metrics in the 10 Major Pharmaceutical Markets* 2022 Market Sales US $508m 5EU $127m Japan $30m China $341m

More information

REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS

REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - Executive Summary Meningococcal Vaccines: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Epidemiology Targeted

More information

REFERENCE CODE GDHCER PUBLICAT ION DATE M AY 2015 GLAUCOMA EPIDEMIOLOGY FORECAST TO 2023

REFERENCE CODE GDHCER PUBLICAT ION DATE M AY 2015 GLAUCOMA EPIDEMIOLOGY FORECAST TO 2023 REFERENCE CODE GDHCER081-15 PUBLICAT ION DATE M AY 2015 GLAUCOMA Executive Summary Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye s optic nerve, resulting in progressive,

More information

REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Albiglutide for Type 2 diabetes in the 10 major pharmaceutical

More information

REFERENCE CODE GDHCER052 PUBLICAT ION DATE NOVEMBER 2013 DIABETIC NEPHROPATHY - EPIDEMIOLOGY FORECAST TO 2022

REFERENCE CODE GDHCER052 PUBLICAT ION DATE NOVEMBER 2013 DIABETIC NEPHROPATHY - EPIDEMIOLOGY FORECAST TO 2022 REFERENCE CODE GDHCER052 PUBLICAT ION DATE NOVEMBER 2013 DIABETIC NEPHROPATHY - Executive Summary Diabetic nephropathy is one of the microvascular complications of diabetes, along with diabetic neuropathy

More information

MQSA Physicist Qualifications. Jon J. Erickson, Ph.D., DABR

MQSA Physicist Qualifications. Jon J. Erickson, Ph.D., DABR 2027 North 36 th Street Saint Joseph, Mo 64506 (86) 390-90 (800) 306-4477 MQSA Physicist Qualifications Jon J. Erickson, Ph.D., DABR Contents Missouri Mammography Physicist Initial Qualifications Certificate

More information

REFERENCE CODE GDHCER022 PUBLICAT ION DATE AUGUST 2013 OVERWEIGHT AND OBESITY - EPIDEMIOLOGY FORECAST TO 2022

REFERENCE CODE GDHCER022 PUBLICAT ION DATE AUGUST 2013 OVERWEIGHT AND OBESITY - EPIDEMIOLOGY FORECAST TO 2022 REFERENCE CODE GDHCER022 PUBLICAT ION DATE AUGUST 2013 OVERWEIGHT AND OBESITY - Executive Summary Obesity is an escalating global public health problem that has reached pandemic proportions. It is caused

More information

REFERENCE CODE GDHC356DFR PUBLICAT ION DATE FEBRUARY 2014 SAPHRIS (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC356DFR PUBLICAT ION DATE FEBRUARY 2014 SAPHRIS (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC356DFR PUBLICAT ION DATE FEBRUARY 2014 SAPHRIS (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSISTO 2022 Executive Summary Saphris: Key Metrics in the Seven Major Pharmaceutical Markets, 2012

More information

REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Neuropathic Pain (NP) in the US The US NP market was valued

More information

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER ONE: EXECUTIVE SUMMARY CHAPTER ONE: EXECUTIVE SUMMARY X-Ray Analysis Digital X-Ray Evolution Boosting Efficiency Significant Uses Chest X-Rays Economics Cardiovascular Disease Market Analysis Traditional X-Ray Digital X-Ray

More information